Abstract
The dynamics of epidemiological phenomena associated to infectious diseases have long been modelled with different approaches. However, recent pandemic events exposed many areas of opportunity to improve over the existing models. We develop a model based on the idea that transitions between epidemiological stages are alike sampling processes. Such processes may involve more than one subset of the population or they may be mostly dependent on time intervals defined by infectious or clinical criteria. We apply the model to simulate epidemics and obtain realistic case fatality ratios. We also analyse the impact of the proportion of asymptomatic of infected people in the distribution of the total infected population and define a basic reproductive number, which determines the existence of a probabilistic phase transition for the pandemics dynamics. The resulting modelling scheme is robust, easy to implement, and can readily lend itself for extensions aimed at answering questions that emerge from close examination of data trends, such as those emerging from the COVID-19 pandemic, and other infectious diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DGAPA- PAPIIT-UNAM grant IN-228820, MAHV DGAPA- PAPIIT-UNAM grant IN-102822, SIL
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.